GLP-1 receptor agonists were associated with reduced risk of alcohol, cannabis, cocaine, nicotine and opioid use disorders, as well as other substance use disorders, suggesting potential prevention effects across a broad range of substances, according to a study published March 4 in The BMJ.
Researchers from the VA St. Louis Health Care System and Washington University in St. Louis analyzed EHR data from 606,434 veterans over up to three years, comparing GLP-1 receptor agonists with SGLT-2 inhibitors. Seven trials were included for each incident SUD outcome, and one trial was included for adverse outcomes in individuals with preexisting substance use disorder.
Previous observational studies have linked GLP-1 receptor agonist use to lower risk of incident and recurrent alcohol, tobacco and cannabis use disorders.
Here are three things to know:
- Patients taking GLP-1 receptor agonists had a lower risk of the composite outcome for all substance use disorders.
- Among patients with preexisting substance use disorder, GLP-1 receptor agonists were associated with lower risk of emergency department visits, hospitalization admission and mortality.
- Use of GLP-1 receptor agonists was associated with lower risks of drug overdose and suicidal ideation or attempts.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
